OncoMatch/Clinical Trials/NCT07398937
Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC
Is NCT07398937 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Serplulimab + chemotherapy and Nivolumab + chemotherapy for resectable stage ii-iiia squamous nsclc.
Treatment: Serplulimab + chemotherapy · Nivolumab + chemotherapy — This trial is a randomized, controlled, multicenter, open-label study, planning to enroll 116 subjects with resectable stage II-IIIa squamous NSCLC confirmed by histopathology or cytology, aiming to evaluate the efficacy and safety of serplulimab compared to nivolumab combined with chemotherapy in neoadjuvant therapy. This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1036.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitizing mutation
EGFR sensitivity mutation
Required: ALK rearrangement
ALK gene rearrangement
Required: ROS1 rearrangement
ROS1 gene rearrangement
Disease stage
Required: Stage II, IIIA
Performance status
WHO/ECOG 0–1
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07398937 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require EGFR?
Yes, EGFR sensitizing mutation is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK rearrangement is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 rearrangement is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or IIIA is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify